VAISHALIPharmaceuticals
Vaishali Pharma Ltd — Profit & Loss Statement
₹4.88
-9.60%
Vaishali Pharma Ltd Profit & Loss Statement (Annual)
| Metric | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
| Tax Effect Of Unusual Items | -1.14 Cr | 0.00 | 0.00 | -0.46 Cr |
| Tax Rate For Calcs | 0.22 | 0.25 | 0.30 | 0.26 |
| Normalized EBITDA | 8.79 Cr | 11.61 Cr | 8.67 Cr | 6.28 Cr |
| Total Unusual Items | -5.09 Cr | 0.00 | 0.00 | -1.82 Cr |
| Total Unusual Items Excluding Goodwill | -5.09 Cr | 0.00 | 0.00 | -1.82 Cr |
| Net Income From Continuing Operation Net Minority Interest | 0.72 Cr | 6.60 Cr | 4.02 Cr | 1.05 Cr |
| Reconciled Depreciation | 0.51 Cr | 0.50 Cr | 0.46 Cr | 0.43 Cr |
| Reconciled Cost Of Revenue | 74.42 Cr | 54.68 Cr | 63.50 Cr | 46.15 Cr |
| EBITDA | 3.70 Cr | 11.61 Cr | 8.67 Cr | 4.46 Cr |
| EBIT | 3.19 Cr | 11.10 Cr | 8.22 Cr | 4.03 Cr |
| Net Interest Income | -0.88 Cr | -1.00 Cr | -1.19 Cr | -1.37 Cr |
| Interest Expense | 2.27 Cr | 2.26 Cr | 2.49 Cr | 2.63 Cr |
| Interest Income | 1.39 Cr | 1.25 Cr | 1.30 Cr | 1.26 Cr |
| Normalized Income | 4.67 Cr | 6.60 Cr | 4.02 Cr | 2.40 Cr |
| Net Income From Continuing And Discontinued Operation | 0.72 Cr | 6.60 Cr | 4.02 Cr | 1.05 Cr |
| Total Expenses | 75.43 Cr | 54.85 Cr | 65.06 Cr | 48.27 Cr |
| Rent Expense Supplemental | 16000.00 | 0.00 | 0.03 Cr | 0.02 Cr |
| Diluted Average Shares | 10.62 Cr | 10.55 Cr | 10.55 Cr | 10.55 Cr |
| Basic Average Shares | 10.62 Cr | 10.55 Cr | 10.55 Cr | 10.55 Cr |
| Diluted EPS | 0.06 | 0.59 | 0.38 | 0.10 |
| Basic EPS | 0.07 | 0.63 | 0.38 | 0.10 |
| Diluted NI Availto Com Stockholders | 0.72 Cr | 6.60 Cr | 4.02 Cr | 1.05 Cr |
| Net Income Common Stockholders | 0.72 Cr | 6.60 Cr | 4.02 Cr | 1.05 Cr |
| Otherunder Preferred Stock Dividend | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | 0.72 Cr | 6.60 Cr | 4.02 Cr | 1.05 Cr |
| Net Income Including Noncontrolling Interests | 0.72 Cr | 6.60 Cr | 4.02 Cr | 1.05 Cr |
| Net Income Continuous Operations | 0.72 Cr | 6.60 Cr | 4.02 Cr | 1.05 Cr |
| Tax Provision | 0.21 Cr | 2.24 Cr | 1.70 Cr | 0.36 Cr |
| Pretax Income | 0.93 Cr | 8.85 Cr | 5.73 Cr | 1.40 Cr |
| Other Non Operating Income Expenses | 0.38 Cr | 0.33 Cr | 0.05 Cr | 0.15 Cr |
| Special Income Charges | -5.09 Cr | 0.00 | 0.00 | -1.82 Cr |
| Write Off | 5.09 Cr | 0.00 | 0.00 | 1.82 Cr |
| Net Non Operating Interest Income Expense | -0.88 Cr | -1.00 Cr | -1.19 Cr | -1.37 Cr |
| Interest Expense Non Operating | 2.27 Cr | 2.26 Cr | 2.49 Cr | 2.63 Cr |
| Interest Income Non Operating | 1.39 Cr | 1.25 Cr | 1.30 Cr | 1.26 Cr |
| Operating Income | 6.34 Cr | 8.97 Cr | 6.48 Cr | 4.04 Cr |
| Operating Expense | 1.01 Cr | 0.17 Cr | 1.56 Cr | 2.11 Cr |
| Other Operating Expenses | 1.66 Cr | 2.52 Cr | 2.75 Cr | 0.81 Cr |
| Depreciation And Amortization In Income Statement | 0.51 Cr | 0.50 Cr | 0.46 Cr | 0.43 Cr |
| Amortization | 0.12 Cr | 0.10 Cr | 0.13 Cr | 0.13 Cr |
| Depreciation Income Statement | 0.38 Cr | 0.40 Cr | 0.33 Cr | 0.29 Cr |
| Selling General And Administration | 1.03 Cr | 0.91 Cr | 0.50 Cr | 0.47 Cr |
| Selling And Marketing Expense | 0.49 Cr | 0.53 Cr | 0.09 Cr | 0.07 Cr |
| General And Administrative Expense | 0.55 Cr | 0.38 Cr | 0.42 Cr | 0.40 Cr |
| Rent And Landing Fees | 16000.00 | 0.00 | 0.03 Cr | 0.02 Cr |
| Gross Profit | 7.35 Cr | 9.15 Cr | 8.04 Cr | 6.16 Cr |
| Cost Of Revenue | 74.42 Cr | 54.68 Cr | 63.50 Cr | 46.15 Cr |
| Total Revenue | 81.76 Cr | 63.82 Cr | 71.54 Cr | 52.31 Cr |
| Operating Revenue | 81.76 Cr | 63.82 Cr | 71.54 Cr | 52.31 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Vaishali Pharma Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.